Biodelivery Sciences International (MM) (NASDAQ:BDSIW)
Historical Stock Chart
From May 2019 to May 2024
BioDelivery Sciences International, Inc. (NASDAQ: BDSI,
BDSIW), a specialty pharmaceutical company, announced today that it
has priced a public offering of 4,400,000 shares of its common stock
which is anticipated to raise gross proceeds of $8,800,000 million for
the company. The public price per share for the offering is $2.00.
The offering is being underwritten by Ferris, Baker Watts
Incorporated, Maxim Group LLC and GunnAllen Financial, Inc. The
underwriters have been granted an option to purchase up to an
additional 660,000 shares of common stock from the company to cover
over-allotments. If the over allotment option is exercised, of which
no assurances can be given, the additional shares will also be sold at
$2.00 per share and will result in additional gross proceeds to BDSI
of up to $1,320,000.
This communication shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of any
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful.
BioDelivery Sciences International, Inc. is a specialty
biopharmaceutical company that is exploiting its licensed and patented
drug delivery technologies to develop and commercialize, either on its
own or in partnerships with third parties, clinically-significant new
formulations of proven therapeutics targeted at "acute" treatment
opportunities such as pain, anxiety, nausea and vomiting and
infections. The company's drug delivery technologies include: (i) the
patented Bioral(R) nanocochleate technology, designed for a
potentially broad base of applications, and (ii) the patented BEMA(TM)
(transmucosal or mouth) drug delivery technology. The company's
headquarters are located in Morrisville, North Carolina and its
principal laboratory is located in Newark, New Jersey.
Note: Except for the historical information contained herein, this
press release contains, among other things, certain forward-looking
statements, within the meaning of the Private Securities Litigation
Reform Act of 1995, that involve risks and uncertainties. Such
statement may include, without limitation, statements with respect to
the Company's plans, objectives, expectations and intentions and other
statements identified by words such as "may", "could", "would",
"should", "believes", "expects", "anticipates", "estimates",
"intends", "plans" or similar expressions. These statements are based
upon the current beliefs and expectations of the Company's management
and are subject to significant risks and uncertainties, including
those detailed in the Company's filings with the Securities and
Exchange Commission. Actual results may differ from those set forth in
the forward-looking statements. These forward-looking statements
involve certain risks and uncertainties that are subject to change
based on various factors (many of which are beyond the Company's
control).
L.G. Zangani, LLC provides financial public relations service to
the Company. As such L.G. Zangani, LLC and/or its officers, agents and
employees, receives remuneration for public relations and or other
services in the form of monies, capital stock in the Company, warrants
or options to purchase capital in the Company.